Conference Coverage

VIDEO: Slow tapering worked best for stopping SLE immunosuppression


 

AT THE EULAR CONGRESS 2014

PARIS – When physicians withdrew immunosuppressant treatment from lupus patients in long-term remission, a gradual tapering down of their immunosuppressant treatment produced a lower rate of subsequent flares than did faster treatment withdrawal, based on experience with 99 patients treated at the University of Toronto.

"This study has answered a very important question," namely, what approach works best when taking patients with systemic lupus erythematosus who are in long-term remission on immunosuppressant therapy off their treatment, said Dr. Zahi Touma, a rheumatologist at the University of Toronto. When patients had their dose tapered down more gradually, they had a reduced rate of flares and needed less immunosuppressant therapy to restart, compared with patients who withdrew from treatment more quickly.

"This is not a validated approach. It is not yet even published," Dr. Touma cautioned during a video interview at the annual European Congress of Rheumatology. But the apparent advantage of more gradual treatment withdrawal "is something we found in this study," he said.

Dr. Touma said that he had no disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

Higher risk of death seen with oral steroids in RA interstitial lung disease
MDedge Internal Medicine
Giant-cell arteritis patients face high aortic aneurysm dissection risk
MDedge Internal Medicine
Tool predicts lymphoma, death in primary Sjögren’s syndrome patients
MDedge Internal Medicine
Factors that lead to gout often differ in men and women
MDedge Internal Medicine
SSTI guidelines stress diagnostic skill, careful treatment
MDedge Internal Medicine
Eurofever Project takes aim at rare autoinflammatory disorders
MDedge Internal Medicine
Physically demanding jobs link to worse ankylosing spondylitis progression
MDedge Internal Medicine
Low infliximab start dose appears effective in psoriatic arthritis
MDedge Internal Medicine
VIDEO: Sarilumab shows RA safety, efficacy in phase III trial
MDedge Internal Medicine
Live births seen in half of pregnancies exposed to belimumab
MDedge Internal Medicine